CompletedPhase 4NCT07162818
Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy
Studying Vitreoretinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Indonesia University
- Principal Investigator
- Ari Djatikusumo, MDDepartment of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital, Indonesia
- Intervention
- Nepafenac 0.1% eyedrops(drug)
- Enrollment
- 61 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2021
Study locations (1)
- Department of Ophthalmology, Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo Hospital, Jakarta, Jakarta Pusat, Indonesia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07162818 on ClinicalTrials.govOther trials for Vitreoretinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06033703Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal DetachmentMassachusetts Eye and Ear Infirmary
- RECRUITINGPHASE2NCT06541574Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) TrialCincinnati Eye Institute, Southwest Ohio
- RECRUITINGPHASE2NCT05523869Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative VitreoretinopathyUnity Health Toronto
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05660447A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVRWills Eye